Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner

Oncogene

Volumn 32, Issue 8, 2013, Pages 988-997

  Wagner, L ^a   Marschall, V ^b   Karl, S ^a   Cristofanon, S ^b   Zobel, K ^c   Deshayes, K ^c   Vucic, D ^c   Debatin, K M ^a   Fulda, S ^a,b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c GENENTECH INC   (United States)

Author keywords

apoptosis; glioblastoma; RIP1; Smac; temozolomide

Indexed keywords

ANTINEOPLASTIC AGENT; BV6 PEPTIDE; CARMUSTINE; CASPASE; CASPASE 8; CELL PROTEIN; CYTOCHROME C; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; PEPTIDOMIMETIC AGENT; RECEPTOR ACTIVATING PROTEIN 1; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SMALL INTERFERING RNA; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CELL VIABILITY; CHEMOSENSITIZATION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME RELEASE; GENE OVEREXPRESSION; GENE SILENCING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; TRANSCRIPTION INITIATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIOMIMETIC MATERIALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; DOWN-REGULATION; DRUG SYNERGISM; GLIOBLASTOMA; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIAL PROTEINS; NF-KAPPA B; NUCLEAR PORE COMPLEX PROTEINS; OLIGOPEPTIDES; PROGNOSIS; RNA-BINDING PROTEINS;

EID: 84874763808     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.108     Document Type: Article

References (29)

1. DeAngelis LM. Brain tumors. N Engl J Med 2001; 344: 114-123.
2. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007; 25: 4127-4136.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
4. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009; 124: 511-515.
5. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-4811.
6. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 2008; 19: 325-331.
7. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010; 9: 447-464.
8. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAPtargeted therapies for cancer. Oncogene 2008; 27: 6252-6275.
9. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131: 669-681.
10. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682-693.
11. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700.
12. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAILor anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8: 808-815.
13. Giagkousiklidis S, Vogler M, Westhoff MA, Kasperczyk H, Debatin KM, Fulda S. Sensitization for gamma-irradiation-induced apoptosis by second mitochondriaderived activator of caspase. Cancer Res 2005; 65: 10502-10513.
14. Vellanki SH, Grabrucker A, Liebau S, Proepper C, Eramo A, Braun V, et al. Smallmolecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia 2009; 11: 743-752.
15. Karl S, Pritschow Y, Volcic M, Hacker S, Baumann B, Wiesmuller L, et al. Identification of a novel pro-apoptotic function of NF-kappaB in the DNA damage response. J Cell Mol Med 2009; 13: 4239-4256.
16. Shirley S, Micheau O. Targeting c-FLIP in cancer. Cancer Lett 2010 (e-pub ahead of print 9 November 2010).
17. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Disc 2012; 11: 109-124.
18. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693-703.
19. Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 2007; 14: 400-410.
20. Probst BL, Liu L, Ramesh V, Li L, Sun H, Minna JD, et al. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-alpha-dependent manner. Cell Death Differ 2010; 17: 1645-1654.
21. Straub CS. Targeting IAPs as an approach to anti-cancer therapy. Curr Top Med Chem 2011; 11: 291-316.
22. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, et al. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 1997; 57: 4956-4964.
23. Fulda S, Strauss G, Meyer E, Debatin KM. Functional CD95 ligand and CD95 deathinducing signaling complex in activation-induced cell death and doxorubicininduced apoptosis in leukemic T cells. Blood 2000; 95: 301-308.
24. Mohr A, Zwacka RM, Debatin KM, Stahnke K. A novel method for the combined flow cytometric analysis of cell cycle and cytochrome c release. Cell Death Differ 2004; 11: 1153-1154.
25. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, Fulda S. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptorand drug-induced apoptosis. Cancer Res 2008; 68: 6271-6280.
26. Gonzalez P, Mader I, Tchoghandjian A, Enzenmu? ller S, Cristofanon S, Basit F, et al. Impairment of lysosomal integrity by B10, a glycosylated derivative of betulinic acid, leads to lysosomal cell death and converts autophagy into a detrimental process. Cell Death Differ 2012; 19: 1337-1346.
27. Hacker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J, et al. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009; 28: 3097-3110.
28. Berger R, Jennewein C, Marschall V, Karl S, Cristofanon S, Wagner L, et al. NF- {kappa}B is required for Smac mimetic-mediated sensitization of glioblastoma cells for (gamma)}-irradiation-induced apoptosis. Mol Cancer Ther 2011; 10: 1867-1875.
29. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC (ed). Synergism and Antagonism in Chemotherapy. Academic Press: San Diego, CA, USA, 1991, pp 61-102.